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Background: Elevated blood pressure (BP) is a major risk factor for the progression of chronic kidney disease (CKD).
However, little is known about the influence of prehypertension on CKD. In this study, we investigated the
relationship between prehypertension and CKD in a middle-aged Korean population. Furthermore, we prospectively
evaluated the effect of active BP control on deterioration of kidney function during the two-year follow-up.
Methods: The Korean Genome and Epidemiology Study is a community-based prospective cohort study started in
2001, with a follow-up survey conducted every two years. A total of 9509 participants aged 40–69 years were
included in a baseline study. BP was classified according to the Seventh Report of the Joint National Committee
on High BP (JNC-7) categories and CKD was defined as the presence of proteinuria or eGFR< 60mL/min/1.73m2.
A multivariable logistic regression model was used to identify associations between BP and CKD.
Results: The overall prevalence of CKD was 13.2%, and significantly increased with BP level. The
multivariable-adjusted odds ratio of CKD was 1.59 for prehypertension and 2.27 for hypertension, compared with
a normal BP. At the two-year follow-up, among the participants with prehypertension, subjects whose BP was
poorly controlled had a significantly higher risk of eGFR drop (OR, 1.37; 95% CI, 1.13-1.67), as compared to controls.
The prevalence of eGFR drop was 57.8% in the controlled BP group and 66.0% in the poorly-controlled BP group.
Conclusions: Prehypertension, as well as hypertension, is significantly associated with CKD among middle-aged
Koreans. Our results indicate that active control of the blood-pressure of prehypertensive individuals is needed
to prevent deterioration of kidney function.
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Chronic kidney disease (CKD) is associated with all-
cause mortality, progression to end-stage renal disease
(ESRD), cardiovascular disease (CVD), and many
chronic diseases, such as diabetes [1–5].
The prevalence of CKD in the United States has
increased from 10.0% in 1988–1994 to 13.1% in 1999–
2004 [6]. In a population-based cross-sectional epidemiolo-
gic study in Korea, the prevalences of CKD and decreased
kidney function were 13.7% and 5.0%, respectively [7].* Correspondence: mdhypark@gmail.com
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reproduction in any medium, provided the orAccording to the Kidney Disease Outcomes Quality Initia-
tive (KDOQI) guidelines, CKD is defined as a marker of
kidney damage and/or glomerular filtration rate (GFR) <
60mL/min/1.73m2 for at least three months; in addition,
GFR is usually estimated from serum creatinine (Scr)
values alone or prediction equations that take into account
the Scr, age, gender and race [8]. Therefore, use of esti-
mated glomerular filtration rate (eGFR) is commonly
recommended to screen patients with CKD [8,9]. Further-
more, management of high risk patients who have hyper-
tension and diabetes is particularly important [8,9].
Elevated blood pressure (BP) is closely associated with
CKD progression, and lowering of BP may slow down. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
excluded
           6 had missing Scr values 
       496 had incomplete data
           2 had CKD stage 5 (eGFR < 15mL/min/1.73m2)
10,038 participated at baseline examinations
9,509 included for baseline study.
10,013 selected adults aged 40 to 69 years
6,039 included for follow-up study.
8,149 selected adults with complete data
excluded
    2,108 had missing Scr values 
2 had missing BP values
8,603 invited to participate for 2-year follow –up examination
92 died 
814 lost to follow-up
Figure 1 Study participants at baseline and follow-up
examinations.
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that hypertension is involved in CKD, emphasizing the
importance of BP control in improving kidney function
[12–14]. Both Kidney Early Evaluation Program (KEEP)
and National Health and Nutrition Examination Survey
(NHANES) data showed a strong association between
hypertension and kidney disease [14]. The Seventh
Report of the Joint National Committee on High BP
(JNC-7) suggests controlling BP at <130/80 mmHg in
patients with CKD [15]. Recently, a population-based,
cross-sectional study from Singapore demonstrated that
BP is independently associated with CKD, and that
poorly controlled hypertension has a significantly stron-
ger relationship with kidney damage than treated, con-
trolled hypertension [16]. In addition, Higashikuni et al.
found that a BP above 110/75 mmHg was significantly
associated with albuminuria in a Japanese population
without hypertension, but not with eGFR [17].
Although several studies have suggested that hyperten-
sion is a significant risk factor for CKD, little is known
of its association with prehypertension and CKD. In this
study, we investigated the relationship between prehy-
pertension and CKD in a middle-aged Korean pop-
ulation. To determine the effect of BP control on
deterioration of kidney function, we prospectively evalu-




The Korean Genome and Epidemiology Study is a
population-based prospective cohort study for the pur-
pose of investigating the prevalence and risk factors of
chronic disease in Korea, with the support of the Korean
National Institute of Health. The baseline survey was
performed in 2001–2002 on 10038 participants aged
over 40 years and follow-up examinations were con-
ducted every two year. Specimens were collected from
the groups of residents representing each local popula-
tion in a rural and an urban area (Anseong and Ansan,
respectively). We obtained baseline and 2-year follow-up
data from the Center for Genome Science in the
National Institute of Health, Korea. The details of the
present cohort have been described elsewhere [18,19].
Of 10038 participants enrolled in a rural and an urban
area (Anseong and Ansan, respectively), 10013 subjects
between the ages of 40 and 69 were selected to partici-
pate in a baseline survey. After exclusion of six subjects
with missing Scr values, 496 who had incomplete data
and two with CKD stage 5 (eGFR < 15 mL/min/1.73 m2),
9509 participants were included for baseline study. At
the 2-year follow-up examination, 8603 participants
were enrolled in this study after exclusion of 92 death
and 814 lost to follow-up. Of those, 8149 people withcomplete data were selected to participate in a follow-up
survey. We excluded 2108 and two participants with
missing Scr and BP values, respectively. Thus, 6039 sub-
jects were included in the present study (Figure 1). Of
these, 2367 with prehypertension at baseline were selected
and their BP change during two-year follow-up deter-
mined. Subjects were divided into controlled and poorly-
controlled groups. The study protocol was approved by
the Institutional Review Board of the Korea Centers for
Disease Control and Prevention. Written informed con-
sent was obtained from all study participants.
Measurement of BP
Measurement of BP was performed after a 5 min period
of rest using a mercury sphygmomanometer, and two BP
readings were taken from both arms at 30 s intervals.
The average systolic and diastolic BP values of two mea-
surements taken in a sitting position were recorded.
BP was classified according to the Seventh Report
of the Joint National Committee on High BP (JNC-7)
categories [15]; normal BP (<120 mm Hg systolic and
<80 mm Hg diastolic); prehypertension (120 to 139 mm
Hg systolic or 80 to 89 mm Hg diastolic); hypertension
(≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic systolic
or use of antihypertensive medication).
Controlled BP was defined as participants who main-
tained a normal BP, and poorly-controlled BP as those
with prehypertension or hypertension at the two-year
follow-up.
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Demographic, medical and behavioral characteristics
were obtained using a standardized questionnaire, and
included age, sex, cigarette smoking and alcohol intake.
Body weight and height were measured to the nearest
0.1 kg or 0.1 cm and body mass index (BMI) was calcu-
lated as body weight (kg) divided by height (meters)
squared. Waist circumference (WC) was measured at
the midpoint between the ribs and the iliac crest in the
standing position.
Blood samples were collected after an 8–14 h fast.
Fasting plasma glucose (FPG), total cholesterol (TC), tri-
glyceride (TG), high-density lipoprotein cholesterol
(HDL-C) and Scr levels were measured enzymatically,
and low-density lipoprotein cholesterol (LDL-C) levels
were estimated by the Friedwald formula [20]. Protein-
uria tested by the dipstick method was defined as 1 +
or more.
Definitions of CKD and diabetes mellitus (DM)
According to the Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines, CKD is defined as a mar-
ker of kidney damage and/or GFR < 60 mL/min/1.73 m2
for at least three months [8]. We defined CKD as the
presence of proteinuria or eGFR < 60 mL/min/1.73 m2.
CKD stages were classified as follows: stage 1, protein-
uria (≥ 1 +) with eGFR ≥ 90 mL/min/1.73 m2; stage 2,
proteinuria (≥1 +) with eGFR 60–89 mL/min/1.73 m2;
stage 3, eGFR 30–59 mL/min/1.73 m2, and stage 4,
eGFR 15–29 mL/min/1.73m2. eGFR was calculated
using the following equation [8]: eGFR = 186.3 × (Scr in
mg/dL)-1.154 × Age- 0.203 × (0.742 if female). Changes in
kidney function were evaluated using baseline and two-
year follow-up eGFR values. eGFR drop denotes
a decline in eGFR between baseline and the two-year
follow-up.
DM was diagnosed as an FPG ≥126 mg/dl or 2-h post-
challenge plasma glucose (2 h PG) ≥200 mg/dl or
hemoglobin A1C (HbA1C) ≥6.5%, or use of oral hypo-
glycemic agents using the 2010 criteria of the American
Diabetes Association (ADA) [21].
Statistical analysis
The baseline characteristics of subjects were expressed
as means and standard deviations for continuous vari-
ables. Statistical differences between groups were per-
formed by one-way analysis of variance (ANOVA) for
continuous variables and the chi-square test for categor-
ical variables. A multivariable logistic regression model
was used to identify associations between BP and CKD.
C-statistics were calculated to compare the ability of dif-
ferent logistic models to discriminate participants with
and without CKD. After two-year follow-up, the odds
ratio of eGFR drop according to BP change wascalculated by multivariable logistic regression analysis.
Values of P <0.05 were considered to be statistically sig-
nificant. The data were analyzed using the SAS software
(version 9.2; SAS Institute, Cary, North Carolina).
Results
Baseline characteristics
The baseline characteristics of the participants according
to BP category are shown in Table 1. Of 9509 partici-
pants, there were 3792 normotensive (39.9%), 3873 pre-
hypertensive (40.7%) and 1844 hypertensive (19.4%)
subjects. The mean age of subjects was 52 years, 47.9%
were male and their mean BMI was 24.6 kg/m2. The
BMI, WC, FPG, TC, LDL-C and TG levels were
increased when BP level was high. Hypertensive partici-
pants were more likely to have a history of DM (11.5%
in the prehypertension group and 19.3% in the hyperten-
sion group). Of all subjects, 25.8% were current smokers
and 47.7% were alcohol drinkers. The mean GFR esti-
mated using the Modification of Diet in Renal Disease
(MDRD) equation was 74.0 ± 14.0 mL/min/1.73 m2, and
was lowest in the hypertension group. The proportion of
individuals with eGFR <60 mL/min/1.73 m2 in the nor-
mal BP, prehypertension and hypertension groups were
5.6%, 11.4% and 23.3%, respectively. Two-hundred and
seventeen subjects (2.3%) had proteinuria (≥1+), which
was more prevalent in subjects with hypertension than
in those with a normal BP.
Prevalence of CKD
The overall prevalence of CKD stages 1 to 4 was 13.2%,
and increased significantly with BP level (P trend
<0.001). CKD prevalence according to stage was 13.8%
in stages 1 and 2, 85.4% in stage 3, and 0.8% in stage 4.
Participants with hypertension showed the highest CKD
prevalence. There was a gender difference in CKD
prevalence (3.5% in males and 22.2% in females).
Females had a higher prevalence of CKD in all categories
(Table 2).
Results of multivariable logistic regression analysis
of CKD
The results of multivariable logistic regression analysis
of CKD according to BP category are presented in
Table 3. The multivariable-adjusted odds ratio (OR) of
CKD was 1.59 (95% CI, 1.29-1.95) in subjects with pre-
hypertension, and 2.27 (95% CI, 1.80-2.86) in subjects
with hypertension, compared with those with a normal
BP. Both prehypertension and hypertension showed sig-
nificant positive associations with CKD after adjustment
for age, sex, BMI, FPG, TC, TG, HDL-C, WC, and smok-
ing and alcohol drinking habits. The c-statistic was 0.90
in the multivariable-adjusted Model 3, which had a
Table 1 Mean values of baseline characteristics according to BP category







Age (years) 52.1 ± 8.9 49.0 ± 7.9 52.8 ± 8.8 56.9 ± 8.2 <0.001
40-49 4557 (47.9) 2393 (63.1) 1730 (44.7) 434 (23.5)
50-59 2481 (26.1) 847 (22.3) 1042 (26.9) 592 (32.1)
60-69 2471 (26.0) 552 (14.6) 1101 (28.4) 818 (44.4)
Gender, male 4566 (48.0) 1594 (42.0) 2164 (55.9) 808 (43.8) <0.001
BMI (kg/m2) 24.6 ± 3.1 23.8 ± 2.9 24.7 ± 3.1 25.8 ± 3.3 <0.001
WC (cm) 82.6 ± 8.8 79.5 ± 8.2 83.6 ± 8.4 86.7 ± 8.5 <0.001
Diabetes 1069 (11.2) 267 (7.0) 447 (11.5) 355 (19.3) <0.001
Current smokers 2455 (25.8) 960 (25.3) 1125 (29.1) 370 (20.1) <0.001
Alcohol drinkers 4535 (47.7) 1715 (45.2) 2016 (52.1) 804 (43.6) <0.001
SBP (mmHg) 121.3 ± 18.4 105.5 ± 8.2 125.9 ± 9.9 144.4 ± 17.6 <0.001
DBP (mmHg) 80.3 ± 11.4 70.2 ± 6.0 84.2 ± 6.5 92.7 ± 10.7 <0.001
FPG (mg/dL) 87.3 ± 21.4 84.7 ± 19.1 88.1 ± 21.3 91.3 ± 25.3 <0.001
TC (mg/dL) 191.5 ± 35.7 186.6 ± 34.1 193.2 ± 35.7 198.3 ± 37.3 <0.001
HDL-C (mg/dL) 44.8 ± 10.1 45.3 ± 9.9 44.7 ± 10.1 43.9 ± 10.3 <0.001
LDL-C (mg/dL) 114.6 ± 33.6 113.2 ± 31.5 114.6 ± 34.2 117.4 ± 36.0 <0.001
TG (mg/dL) 161.0 ± 103.0 140.5 ± 89.9 169.9 ± 109.9 184.7 ± 105.3 <0.001
Scr (mg/dL) 1.00 ± 0.10 0.99 ± 0.10 1.00 ± 0.11 1.00 ± 0.20 <0.001
eGFR (mL/min/1.73 m 2) 74.0 ± 14.0 73.9 ± 14.0 75.2 ± 13.8 71.6 ± 13.9 <0.001
≥90 523 (5.5) 219 (5.8) 210 (5.4) 94 (5.1)
60-89 7903 (83.1) 3361 (88.6) 3222 (83.2) 1320 (71.6)
30-59 1073 (11.3) 212 (5.6) 439 (11.3) 422 (22.9)
15-29 10 (0.1) 0 (0.0) 2 (0.1) 8 (0.4)
Proteinuria(≥1+) 217 (2.3) 45 (1.2) 92 (2.4) 79 (4.3) <0.001
Data are expressed as mean ± SD or percentage. One-way ANOVA was used for continuous variables.
BP categories were defined as follows: Normal BP, SBP <120 mmHg and DBP <80 mmHg; Prehypertension, SBP 120–139 mmHg or DBP 80–89 mmHg;
Hypertension, SBP ≥140 mmHg or DBP ≥90 mmHg or use of antihypertensive medications.
Kim et al. BMC Public Health 2012, 12:960 Page 4 of 8
http://www.biomedcentral.com/1471-2458/12/960better discrimination capability than the unadjusted
model (c-statistic of 0.66).
Odds ratio for eGFR drop during the two-year follow-up
Table 4 shows the odds ratio (OR) for eGFR drop
according to the change of BP during the two-year fol-
low-up. Among all subjects included in the follow-up
study, 3133 had controlled BP (normal BP at two-year
follow-up) and 2906 had poorly-controlled BP (prehy-
pertension or hypertension at two-year follow-up). A
total of 1644 (52.5%) subjects in the controlled and 1827
(62.9%) in the poorly-controlled BP groups experienced
a drop in eGFR. According to the multivariable logistic
regression analysis, subjects whose BP was not con-
trolled had a significantly higher risk of eGFR drop (OR,
1.22; 95% CI, 1.08-1.38) when the controlled BP group
was used as a reference. Of 2367 subjects with prehy-
pertension, 857 had controlled BP (normal BP at two-
year follow-up) and 1510 had poorly-controlled BP(prehypertension or hypertension at two-year follow-up).
The prevalence of eGFR drop was 57.8% in the con-
trolled BP group and 66.0% in the poorly-controlled BP
group. Compared to subjects with controlled BP, the risk
of eGFR drop increased by 1.37 (95% CI, 1.13-1.67)
times for those with poorly-controlled BP after adjust-
ment for age, sex, BMI, FPG, TC, TG, HDL-C, WC, and
smoking and alcohol drinking habits. The c-statistics in
multivariable-adjusted Model 3 showed the best discrim-
ination capability.Discussion
The purpose of this study was to examine the relation-
ship between BP and CKD in a middle-aged Korean
population. We found a strong and independent associ-
ation between prehypertension, as well as hypertension,
and CKD. Our data also indicated that the risk of eGFR
drop at the two-year follow-up was significantly greater
Table 2 Prevalence of CKD according to BP category








No-CKD 8252 (86.8) 3541 (93.4) 3357 (86.7) 1354 (73.4) <0.001
All CKD 1257 (13.2) 251 (6.6) 516 (13.3) 490 (26.6)
Stages 1 and 2 174 (13.8) 39 (15.5) 75 (14.5) 60 (12.2)
Stage 3 1073 (85.4) 212 (84.5) 439 (85.1) 422 (86.1)
Stage 4 10 (0.8) 0 (0.0) 2 (0.4) 8 (1.6)
Males (n=4566)
No-CKD 4408 (96.5) 1571 (98.6) 2088 (96.5) 749 (92.7) <0.001
All CKD 158 (3.5) 23 (1.4) 76 (3.5) 59 (7.3)
Stages 1 and 2 111 (70.3) 20 (87.0) 53 (69.7) 38 (64.4)
Stage 3 44 (27.8) 3 (13.0) 23 (30.3) 18 (30.5)
Stage 4 3 (1.9) 0 (0.0) 0 (0.0) 3 (5.1)
Females (n=4943)
No-CKD 3844 (77.8) 1970 (89.6) 1269 (74.3) 605 (58.4) <0.001
All CKD 1099 (22.2) 228 (10.4) 440 (25.8) 431 (41.6)
Stages 1 and 2 63 (5.7) 19 (8.3) 22 (5.0) 22 (5.1)
Stage 3 1029 (93.6) 209 (91.7) 416 (94.5) 404 (93.7)
Stage 4 7 (0.6) 0 (0.0) 2 (0.5) 5 (1.2)
Data are expressed as n (%) and tested by chi-square test at P < 0.05.
CKD was defined as estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m2 and/or the presence of proteinuria (≥1+).
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beginning with prehypertensive participants.
In this study of 9509 Koreans aged 40–69 years, the
prevalence of CKD was 13.2%, similar to the results of
an epidemiologic study in urban Korea, which reported
an overall CKD prevalence of 13.7% [7]. The prevalence
of CKD was greater in females than in males (3.5% in
males and 22.2% in females) as in other Korean popula-
tion studies [22]. This discrepancy may be possibly
explained by the increased filtration fraction in men,
which may contribute to maintain the GFR [23,24].
In addition, results from NHANES 1999–2004 in the






Normal BP 1.00 (reference) 1.00 (refe
Prehypertension 2.17 (1.85-2.54)* 1.69 (1.38
Hypertension 5.11 (4.33-6.02)* 2.52 (2.02
c-statistic 0.66 0.8
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex and BMI.
Model 3: adjusted for age, sex, BMI, FBG, TC, TG, HDL-C, WC, current smokers and a
*P <0.001.stages 1 to 4 was 13.1% [6]. Among Australian adults
aged 25 years or older, approximately 16% had at least
one indicator of kidney damage [25]. The prevalence of
CKD differs among ethnic groups, and the Asian popula-
tion had a relatively high prevalence [26]. It is estimated
that, in Japan, approximately 19% of the adult population
has stages 3 to 5 CKD [27], and the prevalence of CKD in
Beijing was 12.9% [28]. Furthermore, in the NHANES
1999–2006 in the US, 17.3% and 22.0% of those with pre-
hypertension and undiagnosed hypertension, respectively,
had CKD as determined by eGFR or albuminuria [29].
We used the MDRD equation to estimate GFR be-








rence) 1.00 (reference) 1.00 (reference)
-2.06)* 1.68 (1.37-2.06)* 1.59 (1.29-1.95)*
-3.13)* 2.49 (1.99-3.12)* 2.27 (1.80-2.86)*
9 0.89 0.90
lcohol drinkers.

















Controlled BPb 3133 1644 (52.5) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Poorly-controlled BPc 2906 1827 (62.9) 1.53 (1.38-1.70)** 1.31 (1.16-1.47)** 1.23 (1.09-1.39)** 1.22 (1.08-1.38)*
c-statistic 0.55 0.74 0.75 0.76
Prehypertension
Controlled BPb 857 495 (57.8) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Poorly-controlled BPc 1510 997 (66.0) 1.42 (1.20-1.69)** 1.39 (1.15-1.69)** 1.35 (1.11-1.63)* 1.37 (1.13-1.67)*
c-statistic 0.54 0.74 0.75 0.76
aeGFR drop denotes the decline in eGFR between baseline and the two-year follow-up.
(Changes in eGFR (Δ) = eGFR at two-year follow-up – eGFR at baseline).
bControlled BP was defined as participants who had a normal BP at the two-year follow-up.
cPoorly-controlled BP was defined as participants who were prehypertensive or hypertensive at the two-year follow-up.
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex and BMI.
Model 3: adjusted for age, sex, BMI, FBG, TC, TG, HDL-C, WC, current smokers and alcohol drinkers.
*P<0.01, **P<0.001.
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Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [30], the mean eGFR and preva-
lence of CKD was similar to our results [see Additional
file 1, Additional file 2]. In addition, when we applied
the equations for Korean population [31], the mean
eGFR differed from those by the MDRD equation and
the prevalence of CKD was lower than in our results, es-
pecially in females [see Additional file 1, Additional file
3, Additional file 4]. However, the equations for Korean
population may need to be evaluated its validity in a
variety of population with larger sample size.
We found that CKD prevalence increased with BP
level; normotensive subjects showed the lowest preva-
lence and hypertensive subjects the highest (6.6, 13.3
and 26.6% for normal BP, prehypertension and hyperten-
sion, respectively).
Hypertension is a well-known risk factor for CKD pro-
gression [12–14]. However, the influence of BP on CKD
in the general population in Korea has not been thor-
oughly evaluated. In addition, whether prehypertension
has an effect on CKD remains controversial. In this
study, we focused particularly on the risk of CKD in pre-
hypertensive subjects.
Several cohort studies provided strong epidemiologic
evidence regarding the risk of ESRD across the BP cat-
egories. Our results were consistent with those of an
earlier study, which reported that the risk of ESRD was
increased even with normal but not optimal and high-
normal levels, as well as hypertension [32,33]. In our
data, a multiple logistic regression analysis indicated that
prehypertensive and hypertensive participants had a
~1.6 and ~2.3 times increased risk of CKD. Moreover,studies from the Asia-Pacific region reported that high
BP was the strongest risk factor (>80% greater) for renal
death, indicating the importance of risk factors for CKD
in Asia [34]. Recent studies of the combined effect of
prehypertension and obesity on CKD risk showed that
prehypertensive and obese subjects were at increased
risk of CKD [35,36].
Our follow-up results showed that subjects with
poorly-controlled BP were more likely to have a
decreased eGFR compared with those with controlled
BP. The risk of eGFR drop was significantly increased
among the poorly-controlled BP group in all, and prehy-
pertensive participants (Table 4). These findings support
the JNC-7 recommendation: a reduction in BP to <130/
80 mmHg for CKD patients to prevent cardiovascular
disease outcomes [15]. The MDRD trial demonstrated a
beneficial effect of BP control on progression of chronic
kidney disease; this may support our findings. In a long-
term follow-up of participants with a moderately- to
severely-decreased GFR, as compared to baseline, those
with a reduced target BP had a delayed onset of kidney
failure and the composite outcome, as compared with
the usual-target group [37]. Also, effective control of BP
using antihypertensive agents such as angiotensin-
converting enzyme inhibitors (ACEI), reduced protein-
uria and ameliorated GFR [38].
Interestingly, the risk of CKD significantly increased in
prehypertensive subjects, and those with poorly con-
trolled BP had a higher risk of eGFR drop at the two-
year follow-up. That is, the increased CKD risk begins at
a near-normal BP; therefore, those individuals may be
considered for active BP control to reduce the burden of
kidney disease.
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ive community-based cohort study which evaluated the
association between BP and CKD across the range of BP.
However, there were also some limitations to this
study. First, the study population consisted only of those
aged 40–69 years. Nevertheless, our results may be
representative of the general population in Korea
because the data were from a community-based pro-
spective cohort study, which may have minimized the
sampling bias effect. Second, Scr and proteinuria were
measured only once. According to the K/DOQI guide-
lines, CKD is defined as a GFR <60 mL/min/1.73 m2 or
kidney damage for at least three months; therefore, Scr
and proteinuria should be evaluated more than once.
Thus, there might be an underestimation or overesti-
mation of the prevalence of CKD in both males and
females. Third, the MDRD equation has not been vali-
dated in the Korean population. Therefore, eGFR calcu-
lation using the MDRD equation might be inaccurate.
Fourth, each participant’s BP measurement was based
on only two readings of a single day. Also, we only eval-
uated in a state of BP control with BP values and self-
reported medication at a baseline and 2-year follow-up.
Therefore, the misclassification of BP may be possible
and it might be underestimated or overestimated the
prevalence of controlled BP and poorly-controlled BP.
Conclusions
Prehypertension, as well as hypertension, is significantly
associated with CKD among middle-aged Koreans. Our
results indicate that active control of the blood-pressure
of prehypertensive individuals is necessary to prevent
deterioration in kidney function. Therefore, we suggest
that active blood-pressure control may play an import-
ant role in prevention of CKD.
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Diet in Renal Disease; SBP: Systolic Blood Pressure; DBP: Diastolic Blood
Pressure.
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